Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer

Current Medicinal Chemistry

Volumn 17, Issue 30, 2010, Pages 3476-3487

  Jiao, J ^a   Xiang, H ^a   Liao, Q ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Aromatase; Aromatase inhibitors; Estrogen dependent breast cancer; Nonsteroidal; Postmenopausal women

Indexed keywords

1 (4,4' DICYANOBENZHYDRYL)IMIDAZOLE; 19 HYDROXYANDROSTENEDIONE; 19 OXOANDROSTENEDIONE; 4 [N (4 BROMOBENZYL) N (1,2,4 TRIAZOL 4 YL)AMINO]BENZONITRILE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; BIOCHANIN A; CHROMONE DERIVATIVE; COUMARIN DERIVATIVE; ESTRONE; ESTRONE DERIVATIVE; EXEMESTANE; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; GENISTEIN; GOSSYPETIN; ISOFLAVONE DERIVATIVE; LETROZOLE; LIAROZOLE; LIQUIRITIGENIN; MYRICETIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; STX 64; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOROZOLE;

ARTICLE; BREAST CANCER; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ESTROGEN SYNTHESIS; HUMAN; POSTMENOPAUSE;

ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHROMONES; COUMARINS; FEMALE; FLAVONOIDS; HUMANS; NITRILES; RECEPTORS, ESTROGEN; SULFONAMIDES; TRIAZOLES;

EID: 77957947836     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710792927877     Document Type: Article

References (105)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M. J. Cancer statistics. CA-Cancer. J. Clin., 2006, 56, 106-130.
2. Van Landeghem, A.A.J.; Poortman J; Poortman, M; Thijssen, J.H.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer. Res., 1985, 45, 2900-2906.
3. Henderson, B.E.; Ross, R.K.; Pike, M.C.; Casagrande, J.T. Casagrande endogenous hormones as a major factor in human cancer. Cancer. Res., 1982, 42, 3232-3239.
4. Santen, R.J.; Manni, A.; Harvey, H.; Redmond, C. Endocrine treatment of breast cancer in women. Endocr. Rev., 1990, 11, 221-265.
5. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005, 365(9472), 1687-1717.
6. Nadji, M.; Gomez-Fernandez, C.; Ganjei-Azar, P.; Morales, A.R. Immunohistochemistry of oestrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am. J. Clin. Pathol., 2005, 123, 21-27.
7. Tianlin Wang, Qidong You, Frank Shu-gui Huang, Hua Xiang. Recent advances in selective estrogen receptor modulators for breast cancer. Mini-rev. Med. Chem., 2009, 9(10), 1191-1201.
8. Simpson, E.R.; Clyne, C.; Rubin, G.; Boon, W.C.; Robertson, K.; Britt, K.; Speed, C.; Jones, M. Aromatase-A brief overview. Annu. Rev. Physiol., 2002, 64, 93-127.
9. Bulun, S.E.; Price, T.M.; Aitken, J; Mahendroo, M.S.; Simpson, E.R. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J. Clin. Endocrinol. Metab., 1993, 77, 1622-1628.
10. Means, G.D.; Mahendroo, M.S.; Corbin, C.J.; Mathis, J.M.; Powell, F.E.; Mendelson, C.R.; Simpson, E.R. Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J. Biol. Chem., 1989, 264(32), 19385-19391.
11. Zhao, Y.; Agarwal, V.R.; Mendelson, C.R.; Simpson, E.R. Transcriptional regulation of CYP19 gene(aromatase) expression in adipose stromal cells in primary culture. J. Steroid Biochem. Mol. Biol., 1997, 61, 203-210.
12. Sebastian, S.; Bulun, S.E. A highly complex organization of the regulatory region of the human CYP19(Aromatase) gene revealed by the human genome project. J. Clin. Endocrinol. Metab., 2001, 86, 4600-4602
13. Ghosh, D.; Griswold, J.; Erman, M; Pangborn, W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature, 2009, 457(8), 219-224.
14. Graham-Lorence, S.; Amarneh, B.; White, R.E.; Peterson. A threedimensional model of aromatase cytochrome P450. J.A. Protein. Sci., 1995, 4(6), 1065-1080.
15. Simpson, E.R.; Mahendroo, M.S.; Means, G.D.; Kilgore, M.W.; Hinshelwood, M.M.; Graham-Lorence, S.; Amarneh, B.; Ito, Y.; Fisher C.R.; Michael, M.D.; Mendelson, C.R.; Bulun, S.E. Aromatase cytochrome P450. Enzyme responsible for estrogen biosynthesis. Endocr. Rev., 1994, 15, 342-355.
16. Simpson, E.R.; Davis, S.R. Minireview: Aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinol, 2001, 142(11), 4589-4594.
17. Harada, N. Aberrant expression of aromatase in breast cancer tissues. J. Steroid Biochem. Mol. Biol., 1997, 61, 175-184.
18. Zhao, Y.; Agarwal, V.R.; Mendelson, C.R.; Simpson, E.R. Transcriptional regulation of CYP19 gene(aromatase) expression in adipose stromal cells in primary culture. J. Steroid Biochem. Mol. Biol., 1997, 61, 203-210.
19. Bulun, S.E.; Chen, D.; Lu, M.; Zhao, H. Aromatase excess in cancers of breast, endometrium and ovary. J. Steroid. Biochem. Mol. Biol., 2007, 106(1-5), 81-96.
20. Brodie, A.M.H.; Lu, Q.; Long, B.J.; Fulton, A.; Chen, T.; Macpherson, N.; DeJong, P.C.; Blankenstein, M. A.; Nortier, J. W. R.; Slee, P. H. T. J.; van de Ven, J.; van Gorp. J. M. H. H., Elbers, J. R. J.; Schipper, M. E. I.; Blijham, G. H.; Thijssen, J. H. Aromatase and COX-2 expression in human breast cancers. J. Steroid. Biochem. Mol. Biol., 2001, 79(1-5), 41-47.
21. Zhou, Y.; Eppenberger-Castori, S.; Marx, C.; Yau, C.; Scott, G.K.; Eppenberger, U.; Benz, C.C. Activation of nuclear factorB(NF B) identifies a high-risk subset of hormone-dependent breast cancers. Int. J. Biochem. Cell. Biol., 2005, 37(5), 1130-1144.
22. Benoit, V.; Relic, B.; de Leval, X.; Chariot, A.; Merville, M.P.; Bours, V. Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene, 2004, 23, 1631-1635.
23. Subbaramaiah, K.; Howe, L.R.; Port, E.R.; Brogi, E.; Fishman, J.; Liu, C.H.; Hla, T.; Hudis, C.; Dannenberg, A.J. HER-2/neu status is a determinant of mammary aromatase activity in vivo: Evidence for a cyclooxygenase-2dependent mechanism. Cancer Res., 2006, 66(10), 5504-5511.
24. Smith, I.E. Aromatase inhibitors-extending the benefits of adjuvant therapy beyond tamoxifen. Breast, 2004, 13, S3-S9.
25. Wong, Z.W.; Ellis, M.J. Brit. First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? J. Cancer., 2004, 90, 20-25.
26. Campos, S.M. Aromatase inhibitors for breast cancer in postmenopausal women. Oncology, 2004, 9, 126-136.
27. Altundag, K.; Ibrahim, N.K. Aromatase Inhibitors in Breast Cancer: An Overview. Oncology, 2006, 11, 553-562.
28. Ingle, J.N.; Suman, V.J. Aromatase inhibitors for therapy of advanced breast cancer. J. Steroid Biochem. Mol. Biol., 2005, 95(15), 113-119.
29. Osborne, C.K.; Schiff, R. Aromatase inhibitors: Future directions. J. Steroid. Biochem. Mol. Biol., 2005, 95(1-5), 183-187.
30. Santen, R.J. Inhibition of aromatase: insights from recent studies. Steroids, 2003, 68(7-8), 559-567.
31. Santen, R.J.; Santner, S.; Davis, B.; Veldhuis, J.; Samojlik, E.; Ruby, E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J. Clin. Endocrinol. Metab., 1978, 47(6), 1257-1265.
32. Samojlik, E.; Veldhuis, J.D.; Wells, S.A.; Santen, R.J. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. J. Clin. Invest., 1980, 65(3), 602-612.
33. Santen, R.J.; Worgul, T.J.; Lipton, A.; Harvey, H.; Boucher, A.; Samojlik, E. Wells, S.A. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann. Intern. Med., 1982, 96(1), 94-101.
34. Brueggemeier, R.W.; Hackett, J.C.; Diaz-Cruz, E.S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev., 2005, 26(3), 331-345.
35. Coombes, R.C.; Kilburn, L.C.; Snowdon, C.F.; Paridaens, R.; Coleman, R.E.; Jones, S.E. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment(Intergroup Exemestane Study): a randomised controlled trial. Lancet, 2007, 369(9561), 559-570.
36. [36] Coombes, R.C.; Hall, E.; Gibson, L.J.; Paridaens, R.;Jassem, J.; Delozier, T.; Jones, S.E.; Alvarez, I.; Bertelli, G.; Ortmann, O.; Coates, A.S.; Emilio Bajetta, E.; Dodwell, D.; Coleman, R.E.; Fallowfield, L.J.; Mickiewicz, E.; Andersen, J.; Lønning, P.E.; Cocconi, G.; Stewart, A.; Stuart, N.; Snowdon, C.F.; Carpentieri, M.; Massimini, G.; Bliss, J.M. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med., 2004, 350(11), 1081-1094.
37. Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J., Muss, H.B.; Piccart, M.J.; Monica Castiglione, M.; Tu, D.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Therasse, P.; Palmer, M.J.; Pater, J.L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med., 2003, 349(19), 1793-1802.
38. Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; Piccart, M.J.; Castiglione, M.; Tu, D.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Cameron, D.A.; Palmer, M.J.; Pater, J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst., 2005, 97(17), 1262-1271.
39. [39] The Breast International Group(BIG) 1-98 Collaborative Group. A Comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med., 2005, 353(26), 2747-2758.
40. Smith, I.E.; Dowsett, M. Aromatase inhibitors in breast cancer. N. Engl. J. Med., 2003, 348, 2431-2442.
41. Untch, M.; Jackisch, C. Optimal treatment strategies in hormoneresponsive early breast cancer: The role of aromatase inhibitors. Onkologie, 2007, 30(1-2), 55-64.
42. Geisler, J.; Lønning, P.E., Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations. J. Steroid Biochem. Mol. Biol., 2005, 95(1-5), 75-81.
43. Spicer, J.; Ellis, P. Towards optimal endocrine therapy for hormone-sensitive breast cancer: Initial versus sequential adjuvant aromatase inhibition. Cancer Lett., 2007, 248(2), 165-174.
44. Goss, P.; von Eichel, L. Summary of aromatase inhibitor trials: The past and future. J. Steroid Biochem. Mol. Biol., 2007, 106(1-5), 40-48.
45. Dixon, J.M. Reducing early recurrence with adjuvant aromatase inhibitors: What is the evidence? Breast, 2008, 17(4), 353-360.
46. Kellis, J.T. Jr.; Vickery, L.E. Inhibition of human estrogen synthetase(aromatase) by flavones. Science, 1984, 225(4666), 1032-1034.
47. Hodek, P.; Trefil, P.; Stiborová, M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact., 2002, 139(1), 1-21.
48. Paoletta, S.; Steventon, G.B.; Wildeboer, D.; Ehrman, T.M.; Hylands, P.J.; Barlow, D.J. Screening of herbal constituents for aromatase inhibitory activity. Bioorg. Med.Chem., 2008, 16(18), 8466-8470.
49. Ibrahim, A.R.; Abul-Hajj, Y.J. Aromatase inhibition by flavonoids. J. Steroid. Biochem. Mol. Biol., 1990, 37(2), 257-260.
50. Sanderson, J.T.; Hordijk, J.; Denison, M.S.; Springsteel, M.F.; Nantz, M.H.; van den Berg, M. Induction and inhibition of aromatase(CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol. Sci., 2004, 82, 70-79.
51. Yahiaoui, S.; Pouget, C.; Fagnere, C.; Champavier, Y.; Habriouxa, G.; Chuliaa, A.J. Synthesis and evaluation of 4-triazolylflavans as new inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(20), 5215-5218.
52. Pouget, C.; Fagnere, C.; Basly, J.P. New aromatase inhibitors. synthesis and inhibitory activity of pyridinyl-substituted flavanone derivatives. Bioorg. Med. Chem. Lett., 2002, 12(7), 1059-1061.
53. Yahiaoui, S.; Fagnere, C.; Pouget, C.; Buxeraud, J.; Chulia, A.J. New 7,8-benzoflavanones as potent aromatase inhibitors: Synthesis and biological evaluation. Bioorg. Med. Chem., 2008, 16(3), 1474-1480.
54. Kao, Y.C.; Zhou, C.; Sherman, M.; Laughton, C.A.; Chen, S. Molecular basis of the inhibition of human aromatase(estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environ. Health Perspect., 1998, 106(2), 85-92.
55. Peterson, G.; Barnes, S. Genistein inhibition of the growth of human breast cancer cells: Independence from estrogen receptors and the multi-drug resistance gene. Biochem. Biophys. Res. Commun., 1991, 179(1), 661-667.
56. Peterson. G.; Barnes, S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ., 1996, 7, 1345-1351.
57. Kim, Y.W.; Hackett, J.C.; Brueggemeier, R.W. Synthesis and inhibitory activity of novel pyridine-containing isoflavones. J. Med. Chem., 2004, 47(16), 4032-4040.
58. Hackett, J.C.; Kim, Y.W.; Su, B.; Brueggemeier, R.W. Synthesis and characterization of azole isoflavone inhibitors of aromatase. Bioorg. Med. Chem., 2005, 13(12), 4063-4070.
59. Gobbi, S.; Cavalli, A.; Rampa, A.; Belluti, F.; Piazzi, L.; Paluszcak, A.; Hartmann, R.W.; Recanatini, M.; Bisi, A. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J. Med. Chem., 2006, 49(15), 4777-4780.
60. Su, B.; Hackett, J.C.; Díaz-Cruz, E.S.; Kim, Y.W.; Brueggemeier, R.W. Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors. Bioorg. Med. Chem., 2005, 13(23), 6571-6577.
61. Wächter, G.A.; Hartmann, R.W.; Sergejew, T.; Grün, G.L.; Ledergerber, D. Tetrahydronaphthalenes: Influence of Heterocyclic Substituents on Inhibition of Steroidogenic Enzymes P450 arom and P450 17. J. Med. Chem., 1996, 39(4), 834-841.
62. Van Wauwe, J.P.; Janssen, P.A.J. Is there a case for P-450 inhibitors in cancer treatment? J. Med. Chem., 1989, 32(10), 2231-2239.
63. Leroux, F. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer. Curr. Med. Chem., 2005, 12(14), 1623-1629.
64. Recanatini, M.; Bisi, A.; Cavalli, A.; Belluti, F.; Gobbi, S.; Rampa, A.; Valenti, P; Palzer, M.; Palusczak, A.; Hartmann, R.W. A New Class of Nonsteroidal Inhibitors: Design and Synthesis of Chromone and Xanthone Derivatives and Inhibition of the P450 Enzymes and 17 -Hydroxylase/ C17,20-Lyase. J. Med. Chem., 2001, 44(5), 672-680.
65. Cavalli, A.; Bisi, A.; Bertucci, C.; Rosini, C.; Paluszcak, A.; Gobbi, S.; Giorgio, E.; Rampa, A.; Belluti, F.; Piazzi, L.; Valenti, P.; Hartmann, R.W.; Recanatini, M. Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J. Med. Chem., 2005, 48(23), 7282-7289.
66. Cavalli, A.; Negri, M.; Schewe, K.E.; Belluti, F.; Piazzi, L.; Hartmann, R.W.; Recanatini, M.; Bisi, A. Imidazolylmethyl benzophenones as highly potent aromatase inhibitors. J. Med. Chem., 2007, 50(15), 3420-3422.
67. Roey, P.V.; Bullion, K.A.; Osawa, Y.; Browne, L.J.; Bowman, R.M.; Braun, D.G. Structure-activity studies of non-steroidal aromatase inhibitors: The crystal and molecular structures of CGS 16949A and CGS 18320B. J. Enzym. Inhib. Med. Chem., 1991, 5(2), 119-132.
68. Borgne, M.L.; Marchand, P.; Delevoye-Seiller, B.; Robert, J.M.; Baut, G.L.; Hartmann, R.W.; Palzer, M. New selective nonsteroidal inhibitors: Synthesis and inhibitory activity of 2,3 or 5-(azolylbenzyl)-1H-indoles. Bioorg. Med. Chem. Lett., 1999, 9(3), 333-336.
69. Marchand, P.; Borgne, M.L.; Palzer, M.; Bauta, G.L.; Hartmann, R. W. Preparation and pharmacological profile of 7-(-azolylbenzyl)1H-indoles and indolines as new aromatase inhibitors. Bioorg. Med. Chem. Lett., 2003, 13(9), 1553-1555.
70. Lézé, M.P.; Palusczak, A.; Hartmann, R.W.; Borgne, M.L. Synthesis of 6or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(16), 4713-4715.
71. Castellano, S.; Stefancich, G.; Ragno, R.; Schewe, K.; Santoriello, M.; Caroli, A.; Hartmann, R.W.; Sbardella, G. CYP19(aromatase): Exploring the scaffold flexibility for novel selective inhibitors. Bioorg. Med. Chem., 2008, 16(18), 8349-8358.
72. Morphy, R.; Rankovic, Z. Designed multiple ligants. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48(21), 6523-6543.
73. Chetrite, G. S.; Cortes-Prieto, J.; Philippe, J. C.; Wright, F.; Pasqualini, J. R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol., 2000, 72(1-2), 23-27.
74. Howarth, N.M.; Purohit, A.; Reed, M.J.; Potter, B. V. L. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem., 1994, 37(2), 219-221.
75. Purohit, A.; Williams, G.J.; Howarth, N.M.; Potter, B.V.L.; Reed, M.J. Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-Osulfamate, biochemistry. Biochemistry, 1995, 34, 11508-11514.
76. Numazawa, M.; Tominaga, T.; Watari, Y.; Tada, Y. Inhibition of estrone sulfatase by aromatase inhibitor-based estrogen 3sulfamates. Steroids, 2006, 71(5), 371-379.
77. Woo, L.W.L.; Howarth, N.M.; Purohit, A.; Hejaz, H.A.M.; Reed, M.J.; Potter. B. V. L. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J. Med. Chem., 1998, 41(7), 1068-1083.
78. Woo, L.W.L.; Purohit, A.; Malini, B.; Reed, M.J.; Potter, B.V.L. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol., 2000, 7(10), 773-791.
79. Purohit, A.; Woo, L.W.L.; Potter, B.V.L.; Reed, M.J. In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res., 2000, 60, 3394-3396.
80. Malini, B.; Purohit, A.; Ganeshapillai, D.; Woo, L.W.L.; Potter, B.V.L.; Reed, M.J. Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates. J. Steroid. Biochem. Mol. Biol., 2000, 75(4-5), 253-258.
81. Okada, M.; Yoden, T.; Kawaminami, E.; Shimada, Y.; Kudoh, M.; Isomura, Y.; Shikama, H.; Fujikur, T. Studies on Aromatase Inhibitors. I. Synthesis and Biological Evaluation of 4-Amino-4H-1, 2, 4triazole Derivatives. Chem. Pharm. Bull., 1996, 44(10), 1871-1879.
82. Woo, L.W.L.; Sutcliffe, O.B.; Bubert, C.; Grasso, A.; Chander, S.K.; Purohit, A.; Reed, M.J.; Potter, B.V.L. First Dual-Steroid Sulfatase Inhibitors. J. Med. Chem., 2003, 46(15), 3193-3196.
83. Woo, L.W.L.; Bubert, C.; Sutcliffe, O.B.; Smith, A.; Chander, S.K.; Mahon, M.F.; Purohit, A.; Reed, M.J.; Potter, B.V.L. Dual aromatase-steroid sulfatase inhibitors. J. Med. Chem., 2007, 50(15), 3540-3560.
84. Woo, L.W.L.; Jackson, T.; Putey, A.; Cozier, G.; Leonard, P.; Acharya, K.R.; Chander, S.K.; Purohit, A.; Reed, M.J.; Potter, B.V.L. Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J. Med. Chem., 2010, 53(5), 2155-2170.
85. De Coster, R.; Wouters, W.; Van Ginckel, R.; End, D.; Krekels, M.; Coene, M.C.; Bowden, C. Experimental studies with liarozole(R 75,251): an antitumoral agent which inhibits retinoic acid breakdown. J. Steroid Biochem. Mol. Biol., 1992, 43(1-3), 197-201.
86. Wouters, W.; Van Dun, J.; Dillen, A.; Coene, M.C.; Cools, W.; De Coster, R. Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res., 1992, 52, 2841-2846.
87. Stearns, M. E.; Wang, M.; Fudge, K. Liarozole and 13-cis-Retinoic Acid Anti-Prostatic Tumor Activity. Cancer.Res., 1993, 53, 3073-3077.
88. Lézé, M.P.; Borgne, M.L.; Pinson, P.; Palusczak, A.; Duflos, M.; Bauta, G.L.; Hartmann, R.W. Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1Hindoles: Potent and selective aromatase inhibitors. Bioorg. Med. Chem. Lett., 2006,16(5), 1134-1137.
89. Saberi, M.R.; Vinh, T.K.; Yee, S.W.; Griffiths, B.J.N.; Evans, P.J.; Simons, C. Potent CYP19(Aromatase) 1-[(Benzofuran-2-yl) (phenylmethyl)pyridine, -imidazole, and -triazole Inhibitors: Synthesis and Biological Evaluation. J. Med. Chem., 2006, 49(3), 1016-1022.
90. Goss, P. E.; Winer, E.P.; Tannock, I. F.; Schwartz, L. H. Randomized phase III trial comparing the new potent and selective thirdgeneration aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J. Clin. Oncol., 1999, 17(1), 52-63.
91. De Jong, P.C.; van de Ven, J.; Slee, P.H.T.J.; Blankenstein, R.A. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer. Res., 1997, 57, 2109-2111.
92. Johnston, S.R.D.; Smith, I.E.; Doody, D.; Jacobs, S.; Robertshaw, H.; Dowsett, M. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res., 1994, 54, 5875-5881.
93. Castellano, S.; Stefancich, G.; Ragno, R.; Schewe, K.; Santoriello, M.; Caroli, A.; Hartmann, R.W.; Sbardella, G. CYP19(aromatase): Exploring the scaffold flexibility for novel selective inhibitors. Bioorg. Med. Chem., 2008, 16(18), 8349-8358.
94. Zhao, Y.; Agarwal, V.R.; Mendelson, C.R.; Simpson, E.R. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase)gene. Endocrinology, 1996, 137, 5739-5742.
95. Díaz-Cruz, E.S.; Shapiro, C.L.; Brueggemeier, R.W. Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J. Clin. Endocrinol. Metab., 2005, 90, 2563-2570.
96. Brueggemeier, R.W.; Díaz-Cruza, E.S.; Li, P.K.; Sugimoto, Y.; Lin, Y.C.; Shapiro, C.L. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J. Steroid Biochem. Mol. Biol., 2005, 95(1-5), 129-136.
97. Su, B.; Díaz-Cruz, E.S.; Landini, S.; Brueggemeier, R.W. Novel Sulfonanilide Analogues Suppress Aromatase Expression and Activity in Breast Cancer Cells Independent of COX-2 Inhibition. J. Med. Chem., 2006, 49(15), 1413-1419.
98. Brueggemeier, R.W.; Su, B.; Sugimoto, Y.; Díaz-Cruz, E.S.; Davis, D.D. Aromatase and COX in breast cancer: Enzyme inhibitors and beyond. J. Steroid Biochem. Mol. Biol., 2007, 106(1-5), 16-23.
99. Su, B.; Díaz-Cruz, E.S.; Landini, S.; Brueggemeier, R.W. Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids., 2008, 73(1), 104-111.
100. Su, B.; Landini, S.; Davis, D.D.; Brueggemeier, R.W. Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. J. Med. Chem., 2007, 50(7), 1635-1644.
101. Su, B.; Tian, R.; Darby, M.V.; Brueggemeier, R.W. Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: Synthesis, biological evaluation, and ligand-based pharmacophore identification. J. Med. Chem., 2008, 51(5), 1126-1135.
102. Su, B.; Darby, M.V.; Brueggemeier, R.W. J. Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer. Comb. Chem., 2008, 10(3), 475-483.
103. Hoult, J. R. S.; Payá, M. Pharmacological and biochemical actions of simple coumarins: Natural products with therapeutic potential. Gen. Pharmacol., 1996, 27(4), 713-722.
104. Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszcak, A.; Hartmann, R.W.; Carotti, A. Design, synthesis, and 3D QSAR of novel potent and selective inhibitors. J. Med. Chem., 2004, 47(27), 6792-6803.
105. Chen, S.; Cho, M.; Karlsberg, K.; Zhou, D.; Yuan, Y.C. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. J. Biol. Chem., 2004, 279(46), 48071-48378.